Want to see TYRA full AI Analyst Report?
TYRA Stock Chart & Stats
$30.63
$0.43(1.40%)
At close: 4:00 PM EDT
$30.63
$0.43(1.40%)
Day’s Range― - ―
52-Week Range$9.96 - $40.65
Previous Close$31.22
Volume473.79K
Average Volume (3M)370.94K
Market Cap
$1.90B
Enterprise Value$1.99K
Total Cash (Recent Filing)$383.47M
Total Debt (Recent Filing)$5.70M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Aug 06, 2026EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.18
Shares Outstanding59,470,383
10 Day Avg. Volume580,167
30 Day Avg. Volume370,944
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)6.05
Price to Sales (P/S)0.00
P/FCF Ratio-16.45
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$49.88Price Target Upside62.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.58
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Sizable Equity CushionTyra's very low debt and substantial equity base provide durable financial flexibility for a clinical-stage biotech. A conservative capital structure reduces interest burden and lowers near-term refinancing pressure, enabling management to prioritize R&D, pursue partnerships, or fund trials without immediate debt constraints.
Recent $126M Equity Financing Improved LiquidityA material equity infusion meaningfully extends operational runway, lowering the immediacy of fundraising risk and allowing the company to progress clinical programs and de-risk assets. For a pre-revenue developer, sizable recent financing supports execution of milestones that create long-term strategic optionality.
Proprietary SNÅP Platform And FGFR-focused PipelineA focused pipeline addressing FGFR biology and acquired resistance is a structural advantage given unmet needs in oncology. The SNÅP discovery platform can improve target-to-candidate efficiency, and multiple clinical programs (TYRA-300, TYRA-200) provide diversified 'shots on goal' and make partnering or licensing outcomes more attainable over time.
Bears Say
Pre-revenue With Widening Net LossesThe company has no product revenue and losses have grown materially, reflecting escalating R&D and operating commitments. Without revenue, continued negative results increase dependency on external financing to sustain operations, raising the risk that capital constraints could force program delays, reprioritization, or dilution.
High And Rising Cash BurnSustained operating and free cash outflows near ~$100M TTM create structural funding requirements. Even with recent financing, persistent high burn constrains strategic flexibility, heightens the probability of future equity raises, and forces trade-offs between advancing multiple programs versus concentrating limited resources on highest-return assets.
Negative Returns On Equity Indicate Dilution RiskA TTM ROE around -41% shows capital is being consumed rather than generating shareholder returns. For investors and potential partners, prolonged negative ROE signals that investments have yet to create value, increasing the likelihood of future dilution, tougher financing terms, or the need for high-value partnerships to restore capital efficiency.
Tyra Bioscience News
TYRA FAQ
What was Tyra Bioscience’s price range in the past 12 months?
Tyra Bioscience lowest stock price was $9.96 and its highest was $40.65 in the past 12 months.
What is Tyra Bioscience’s market cap?
Tyra Bioscience’s market cap is $1.90B.
When is Tyra Bioscience’s upcoming earnings report date?
Tyra Bioscience’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.
How were Tyra Bioscience’s earnings last quarter?
Tyra Bioscience released its earnings results on May 13, 2026. The company reported -$0.64 earnings per share for the quarter, missing the consensus estimate of -$0.588 by -$0.052.
Is Tyra Bioscience overvalued?
According to Wall Street analysts Tyra Bioscience’s price is currently Undervalued.
Does Tyra Bioscience pay dividends?
Tyra Bioscience does not currently pay dividends.
What is Tyra Bioscience’s EPS estimate?
Tyra Bioscience’s EPS estimate is -0.65.
How many shares outstanding does Tyra Bioscience have?
Tyra Bioscience has 59,470,383 shares outstanding.
What happened to Tyra Bioscience’s price movement after its last earnings report?
Tyra Bioscience reported an EPS of -$0.64 in its last earnings report, missing expectations of -$0.588. Following the earnings report the stock price went up 3.785%.
Which hedge fund is a major shareholder of Tyra Bioscience?
Currently, no hedge funds are holding shares in TYRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tyra Bioscience Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.88 (62.83% Upside)
$49.88 (62.83% Upside)
Hedge Fund Trend
Increased
By 2.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.6%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
40.61%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
19.96%
Trailing 12-Months
Company Description
Tyra Bioscience
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
TYRA Stock 12 Month Forecast
Average Price Target
$49.88
▲(62.83% Upside)
Technical Analysis
Ownership Overview
29.85% Insiders
16.39% Mutual Funds
7.93% Other Institutional Investors
35.71% Public Companies and
Individual Investors